98%
921
2 minutes
20
Herein, we fabricated fluorescent gold nanoclusters (Au NCs) by using trypsin as a ligand. The fabricated trypsin-Au NCs emit bright red color fluorescence upon the exposure of 365 nm UV light. The trypsin-Au NCs are stable and well dispersed in water, which exhibited strong red emission peak at 665 nm upon excitation wavelength of 520 nm. The red fluorescence of trypsin-Au NCs was greatly quenched by the addition of multiple analytes such as drugs (carbidopa and dopamine) and three divalent metal ions (Cu, Co and Hg ion). As a result, a novel fluorescence "turn-off" probe was developed for the detection of the above analytes with good selectivity and sensitivity. This method exhibits the detection limits for carbidopa, dopamine, Cu, Co and Hg ions are 6.5, 0.14, 5.2, 0.0078, and 0.005 nM, respectively. The trypsin-Au NCs were successfully applied to detect drugs (carbidopa, and dopamine) in pharmaceutical samples and metal ions (Cu, Co and Hg ion) in biofluids and water samples, exhibiting good precision and accuracy, which offers a facile analytical strategy for assaying of the above analytes in pharmaceutical and biological samples.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.saa.2019.02.078 | DOI Listing |
Front Hum Neurosci
August 2025
Center for Drug Discovery and Development Sciences, Research Organization of Science and Technology, Ritsumeikan University, Kyoto, Japan.
Emerging evidence suggests that striatal striosomes play a key role in the dopaminergic regulation of motor and mental action selection processes, with impairments leading to repetitive stereotyped movements (dystonias), thoughts (obsessions), and behaviors (compulsions). To explore this hypothesis therapeutically, we investigated how idiopathic dystonia and obsessive-compulsive disorder (OCD) respond to a novel dopaminergic treatment using low-dose L-DOPA combined with chlorpromazine (CPZ), which can primarily enhance striosomal D dopamine receptor (DR) signaling in humans. The therapeutic effects of L-DOPA/CPZ were assessed over 1 year in 26 idiopathic dystonia patients (mean age, 55.
View Article and Find Full Text PDFClin Park Relat Disord
July 2025
Department of Neurology, Kindai University, Faculty of Medicine, Japan.
Background: Dysphagia is a potentially fatal symptom of Parkinson's disease (PD) and is characterized by frequent silent aspiration, a known risk factor for aspiration pneumonia. A previous study has reported that the dopamine agonist rotigotine (levodopa equivalent dose of 60 mg/day) delivered via transdermal patch improves swallowing function more effectively than oral levodopa (200 mg/day), highlighting the importance of continuous dopaminergic stimulation (CDS) in managing dysphagia. To achieve CDS, patients with advanced PD may require device-assisted therapies (DATs), including levodopa-carbidopa intestinal gel (LCIG), which have significantly improved swallowing function on some measures.
View Article and Find Full Text PDFJ Mol Histol
August 2025
Neuropharmacology Unit, Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Sango-Ojo Road, Ibadan, Oyo State, Nigeria.
The loss of dopamine due to progressive degeneration of dopaminergic neurons is the primary cause of neurobehavioral disturbances in Parkinson's disease (PD). Current research focuses on developing neuroprotective agents that can halt the progressive degeneration of dopaminergic neurons in PD, as its cure remains elusive. Several herbal products, including extracts from Sorghum bicolor, which possess neuroprotective properties, are being investigated as potential agents for PD.
View Article and Find Full Text PDFNeuropharmacology
November 2025
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.
The current study aimed to evaluate the neuroprotective potential of sinapic acid (SA) administration in alleviating Parkinson's disease (PD) features, focusing on its effects in amelioration of endoplasmic reticulum (ER) stress-mediated unfolded protein response (UPR) signaling, oxidative stress, and alpha-synucleinopathy in chronic ROT-induced PD rats. PD was induced using 11 ROT injections (1.5 mg/kg/48h; s.
View Article and Find Full Text PDFExpert Opin Drug Deliv
August 2025
Neurodegenerative Diseases Unit, Department of Neuroscience, Padova Neuroscience Center (PNC), University of Padova, Padova, Italy.
Introduction: Oral dopaminergic treatment is the cornerstone of Parkinson's disease (PD) management. However, progressive shortening of oral levodopa's effect, along with the limited efficacy of enzyme inhibitors and dopamine agonists, does not allow to adequately control motor and non-motor complications characterizing advanced PD. At this stage, device-aided therapies (DATs), including infusion treatments, are warranted to guarantee an adequate quality of life.
View Article and Find Full Text PDF